首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1122375

腎癌治療市場：按療法、按藥理學分類（血管生成抑製劑、mTOR 抑製劑、細胞因子等）、按分銷渠道、按地區 - 規模、份額、前景、機會分析，2022-2030 年

Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others ), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月03日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

腎癌是一種腎細胞不受控制地生長、限制正常細胞功能的疾病。腎癌的風險因素包括吸煙、肥胖、工作場所接觸鎘、一些除草劑、有機溶劑，尤其是三氯乙烯、高血壓、晚期腎病、某些藥物、遺傳和遺傳風險因素。透明細胞腎細胞癌是最常見的腎細胞癌。在實驗室觀察時，構成透明細胞腎細胞癌的細胞看起來非常蒼白或透明。在預測期內，這些風險因素的暴露增加為腎癌治療市場提供了有利可圖的增長前景。根據美國癌症協會 2018 年 1 月的數據調查，腎癌是美國男性和女性最常見的 10 種癌症之一。男性患腎癌的風險更高，大約每 48 名男性中有 1 人和每 83 名女性中有 1 人面臨終生患腎癌的風險。腎細胞癌 (RCC) 是最常見的腎癌類型。相同的數據還表明，10 個腎癌中約有 9 個是腎細胞癌。

市場動態

主要參與者正在努力開發癌症免疫治療藥物，以對抗癌症並提高免疫力。例如，2019 年 1 月，醫療保健公司 F. Hoffmann-La Roche 宣布發現 PD-L1，一種防止癌症免疫逃逸的配體，可用作腎細胞癌治療的輔助治療。 Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A)，一種靶向程序性死亡配體 1) 的人工單克隆抗體。 Tecentriq 處於 III 期試驗階段。

本研究的主要特點

本報告對全球腎癌藥物市場進行了深入分析，顯示了市場規模（十億美元）和復合年增長率 (CAGR%)。
它還揭示了不同細分市場的潛在收入機會，並概述了一個有吸引力的市場投資建議矩陣。
它還提供有關市場驅動因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭策略等方面的重要見解。
它根據以下參數描述全球腎癌治療市場的主要參與者 - 公司簡介、產品組合、主要亮點、財務業績和戰略。
本研究涵蓋的主要公司包括輝瑞公司、諾華國際公司、基因泰克公司、Active Biotech AB、安進公司、拜耳公司、Cipla Limited、霍夫曼拉羅氏公司、百時美施貴寶公司、衛材株式會社和 Exelixis, Inc.
我們相信，這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球腎癌治療市場報告針對該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師1。
利益相關者可以通過用於分析全球腎癌治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場快照：按療法分類
- 市場快照：按藥理學分類
- 市場快照：按銷售渠道
- 市場概況：按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

市場動態
- 驅動程序
- 約束因素
- 市場機會
影響分析
市場趨勢
流行病學
主要發展狀況
戰略聯盟和收購
監管場景
保險報銷分析
管道分析

第 4 章全球腎癌藥物市場：冠狀病毒 (COVID-19) 大流行的影響

整體影響
政府舉措
COVID-19 對市場的影響

第 5 章全球腎癌藥物市場：按療法，2017-2030 年

靶向治療
免疫療法
化療

第 6 章全球腎癌藥物市場：按藥理學分類，2017-2030

血管生成抑製劑
mTOR 抑製劑
其他（免疫檢查點抑製劑、CTLA-4 抑製劑、抗代謝物等）

第 7 章。全球腎癌藥物市場：按分銷渠道，2017-2030 年

醫院藥房
零售藥房
在線藥店

第 8 章全球腎癌藥物市場：2017-2030 年各地區

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海合會
以色列
其他中東
非洲
北非
中非
南非

第 9 章競爭格局

熱圖分析
公司簡介
- 輝瑞公司
藥物組合
- 諾華國際公司
醫藥產品組合
- 基因泰克公司
醫藥產品組合
- Active Biotech AB
醫藥產品組合
- 安進公司
醫藥產品組合
- 拜耳公司
藥物組合
- Cipla 有限公司
藥物組合
- 霍夫曼-拉羅氏公司
藥物組合
- 百時美施貴寶公司
藥物組合
- 衛材株式會社
藥物組合
- Exelixis, Inc.
藥物組合

第 10 章

參考資料
調查方法

簡介目錄

Product Code: CMI2399

Kidney cancer or renal carcinoma affects kidney cells to grow out of control and restrict the function of normal cells. Several risk factors associated with kidney cancer include smoking, obesity, workplace exposures substances such as cadmium, some herbicides, and organic solvents, particularly trichloroethylene, high blood pressure, advanced kidney disease, certain medicines, and genetic and hereditary risk factors. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure of these risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period. According to American Cancer Society, January 2018 data findings, kidney cancer was among the 10 most common cancers in the U.S. in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer. Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to same source, around 9 out of 10 kidney cancers were renal cell carcinomas.

Market Dynamics

Key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion, which would be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is in phase III stage.

Key features of the study:

This report provides an in-depth analysis of the global kidney cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation:

Global Kidney Cancer Drugs Market, By Therapy:
- Targeted Therapy
- Immunotherapy
- Chemotherapy
Global Kidney Cancer Drugs Market, By Pharmacological Class:
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
Global Kidney Cancer Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Kidney Cancer Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Pfizer Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis International AG
- Genentech, Inc.
- Active Biotech AB
- Amgen Inc.
- Bayer AG
- Cipla Limited
- Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Exelixis, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Pharmacologic Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Epidemiology
Key Developments
Strategic Collaborations & Acquisitions
Regulatory Scenario
Reimbursement Analysis
Pipeline Analysis

4. Global Kidney Cancer Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Kidney Cancer Drugs Market, By Therapy, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Kidney Cancer Drugs Market, By Pharmacologic Class, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Angiogenesis Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
mTOR Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Kidney Cancer Drugs Market, By Region, 2017 - 2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
North Africa
Central Africa
South Africa